# Phase 11 — final double-check: sandbox acceptance

## Decision

> **PASS for the bounded read-only and negative-authorization acceptance scope; BLOCKED for production release and deployment.**

Phase 11 did not authorize a production deployment, payment or refund activity, SOS/QR/consent activation, financial withdrawal, catalog/governance change, destructive data operation, or access to real-user data. It used only supplied sandbox identities against the production API and retained neither credentials nor personal/clinical response content. The Phase 11 boundary is preserved in full.[1]

## Wave reconciliation

| Wave | Scope | Result | Double-check outcome |
|---|---|---|---|
| 1 | Sandbox authentication, identity reads, owned-order access, patient identity separation, provider identity and owned request queue | **PASS / CONTAINED** | Patient foreign order is `403`; patient credential does not disclose provider identity. [2] |
| 2 | Cross-account lab result and unified-booking reads, unauthenticated order read, patient-to-admin boundary, prescription-list review | **PASS with one blocked live-proof condition** | Foreign lab and unified-booking detail reads are `404`; unauthenticated orders are `401`; patient-to-admin is `403`. Patient1 had no prescription source record, so a live prescription BOLA attempt was not fabricated. [3] |
| 3 | Reversible sandbox workflow mutation | **NOT EXECUTED** | No new, narrowly bounded reversible mutation was specified for this acceptance window. High-risk and otherwise prohibited flows remain excluded by the boundary; this is not counted as a workflow pass. [1] |
| Remediation | Archive-level prescription-detail authorization gap found during Wave 2 | **FIXED AT SOURCE / NOT DEPLOYED** | Participant/privileged-admin authorization and `404` existence hiding are regression-covered; Backend focused 6/6, full 65 suites/370 tests and `nest build` passed. Post-deployment sandbox proof remains required. [4] |

## Current source artifacts

All four tracked archives pass ZIP integrity validation at the current branch head `ca345751cb47cb26724e6c081bb81f58e89ee1a9`.

| Archive | SHA-256 | Integrity | Status |
|---|---|---|---|
| Patient app | `89b11155f1e2161fa6644a868a59dda33b76c611f3a84787bb2a888f19df6040` | **PASS** | No Phase 11 source change. |
| Provider app | `66657e8aeac20a142ebc226e3b978b62a98dc063ec620e0cbfa430a8eca94aee` | **PASS** | No Phase 11 source change. |
| Backend | `2b47f9e7f5c289d3d35d9b211fe0de07f931aa39c08c0006c90cc4e08bdcfac3` | **PASS** | Includes prescription-detail authorization remediation. |
| Admin dashboard | `fafc08e48f9063dcb45775e86b3828e333d32cc46fbefaaae7472f8813f4cad2` | **PASS** | No Phase 11 source change. |

## Release blockers retained

The following are unresolved and independently prevent a production-release decision. They are not overridden by a successful bounded sandbox authorization check.

| Blocker | Required closure |
|---|---|
| Prescription authorization patch | Reviewer/owner deployment with rollback point, then actual Patient1 prescription → Patient2 read proof on the deployed revision. |
| Dependency security findings | Controlled Backend Nest/XLSX and Patient/Provider Expo SDK migrations; Phase 10 records 9 Backend high, 17 Patient high and 13 Provider high findings. [5] |
| Payment | Moyasar live-account activation followed by reviewer-authorized sandbox payment, webhook, idempotency and refund verification. |
| Legal/product contracts | Written owner approval for SOS, QR, consent and location contracts; all remain fail-closed beforehand. |
| Device and store gates | Signed Android/iOS builds, real-device testing, push/call/GPS/LiveKit checks, and app-store submission prerequisites. |
| Human quality gates | Six-language translation, RTL/LTR, accessibility, contrast and premium screen-by-screen design review. |
| Operational release control | Reviewer-authorized deployment, backup/rollback confirmation, production smoke plan and post-deployment monitoring. |

## Phase 11 completion statement

The Phase 11 plan has been double-checked against its authorized boundary, recorded evidence, source/archive contents, current branch history and archive integrity. All eligible read-only and negative-authorization checks are documented. The sole discovered source-level authorization gap was corrected and verified locally, but deliberately remains **operationally open** until a controlled deployment and live proof. Phase 12 may therefore prepare the final readiness report and deployment decision; it must not represent this state as approval to deploy.

## References

[1]: NABDAH_PHASE11_SANDBOX_ACCEPTANCE_BOUNDARY_20260819.md "Phase 11 sandbox acceptance boundary"
[2]: NABDAH_PHASE11_SANDBOX_READONLY_AUTHORIZATION_WAVE1_20260819.md "Phase 11 sandbox read-only authorization wave 1"
[3]: NABDAH_PHASE11_SANDBOX_READONLY_AUTHORIZATION_WAVE2_20260819.md "Phase 11 sandbox read-only authorization wave 2"
[4]: NABDAH_PHASE11_PRESCRIPTIONS_AUTHORIZATION_REMEDIATION_20260819.md "Phase 11 prescription detail authorization remediation"
[5]: NABDAH_PHASE10_FINAL_DOUBLE_CHECK_20260819.md "Phase 10 final double-check"
